Last updated: August 1, 2026
Sonidegib phosphate, marketed as Odomzo by Novartis, is an oral smoothened (SMO) inhibitor approved for adults with locally advanced basal cell carcinoma (laBCC) that has recurred after surgery or radiation therapy, or for patients who are not candidates for those treatments. Its commercial opportunity is limited by a narrow indication, class toxicity, treatment discontinuation, and competition from vismodegib and PD-1 therapy in advanced disease.
The strongest current role for sonidegib is in Hedgehog-pathway-driven laBCC. Evidence in metastatic basal cell carcinoma, medulloblastoma, pancreatic cancer, and other solid tumors has not produced a comparable regulatory or commercial indication. The principal market risks are generic entry, weak demand outside specialist oncology, and the availability of alternative systemic regimens.
What is sonidegib phosphate and how does it work?
Sonidegib phosphate is the phosphate salt of sonidegib, a small-molecule inhibitor of SMO. SMO is a transmembrane protein in the Hedgehog signaling pathway. Aberrant Hedgehog signaling drives most basal cell carcinomas through mutations involving PTCH1, SMO, or related pathway components.
Sonidegib inhibits SMO and reduces downstream activation of GLI transcription factors. The drug is administered orally at 200 mg once daily on an empty stomach.
Key product facts
| Attribute |
Sonidegib phosphate |
| Brand |
Odomzo |
| Active moiety |
Sonidegib |
| Developer |
Novartis |
| Drug class |
Hedgehog pathway inhibitor; SMO antagonist |
| FDA approval |
July 24, 2015 |
| Approved indication |
Locally advanced BCC unsuitable for curative surgery or radiation |
| Standard dose |
200 mg orally once daily |
| Dosage form |
Capsules |
| Primary disease |
Basal cell carcinoma |
| Regulatory pathway |
Standard NDA approval |
| U.S. reference product |
Odomzo |
| Biosimilar pathway |
Not applicable; sonidegib is a small molecule |
The FDA approved sonidegib on the basis of the phase II BOLT study, which evaluated two dose levels in patients with locally advanced or metastatic BCC. The 200-mg dose became the commercial dose because the 800-mg dose produced more toxicity without a sufficient efficacy advantage.[1]
What clinical trials support sonidegib approval?
The pivotal BOLT trial, registered as NCT01327053, was a randomized, double-blind, phase II study in patients with advanced BCC. Patients received sonidegib 200 mg or 800 mg once daily.
At the primary analysis, the investigator-assessed objective response rate in the 200-mg arm was approximately 43% in locally advanced BCC, with a lower response rate in metastatic BCC. With longer follow-up, response durability remained clinically relevant in responding patients, but treatment-related adverse events frequently required dose interruption or discontinuation.[1,2]
BOLT trial profile
| Measure |
Sonidegib 200 mg |
| Trial |
BOLT, NCT01327053 |
| Phase |
Phase II |
| Population |
Locally advanced or metastatic BCC |
| Primary endpoint |
Objective response rate |
| laBCC response |
Approximately 43% at the primary analysis |
| Common toxicities |
Muscle spasms, alopecia, dysgeusia, weight loss, nausea, fatigue |
| Major laboratory concern |
Creatine kinase elevation |
| Key commercial implication |
Efficacy is meaningful, but tolerability limits persistence |
The BOLT data supported a narrower regulatory position than a broad first-line advanced BCC indication. The FDA label requires that patients be unsuitable for surgery or radiation therapy, preserving a specialized treatment setting rather than a mass-market dermatology opportunity.[1]
What is the current clinical-trial landscape for sonidegib?
Clinical development has concentrated on four areas:
- Advanced BCC, including locally advanced and metastatic disease.
- Neoadjuvant or organ-preserving treatment before surgery.
- Combination treatment with immunotherapy or other targeted agents.
- Hedgehog-pathway-dependent tumors outside BCC.
The advanced BCC program has produced the clearest clinical value. Trials in other tumors have generally been exploratory and have not led to major label expansion.
Basal cell carcinoma trials
Studies have examined sonidegib in patients with extensive tumors for whom surgery would cause major functional or cosmetic morbidity. Neoadjuvant use is commercially relevant because tumor shrinkage could make surgery possible or reduce the extent of resection. These studies remain less important to the current label than the BOLT data.
Potential clinical applications include:
- Tumor reduction before definitive surgery.
- Treatment of tumors in anatomically difficult locations.
- Management of patients who cannot tolerate or receive radiation.
- Treatment after prior Hedgehog-pathway inhibitor exposure, although acquired resistance is a major limitation.
Combination and sequencing studies
The principal combination hypothesis is that Hedgehog inhibition may alter the tumor microenvironment and improve the activity of immune checkpoint inhibitors. Evidence remains investigational. Sonidegib has not established a broadly accepted combination regimen with pembrolizumab, cemiplimab, nivolumab, or other checkpoint inhibitors.
The clinical sequencing problem is important. Patients who progress on a Hedgehog inhibitor may develop SMO mutations or downstream pathway resistance. Rechallenge with another SMO inhibitor is therefore unlikely to produce consistent benefit.
Non-BCC development
Sonidegib has been evaluated in medulloblastoma, pancreatic cancer, ovarian cancer, and other solid tumors. These programs have faced common Hedgehog-inhibitor problems:
- Limited activity in unselected populations.
- Insufficient pathway dependence in many tumors.
- Dose-limiting muscle toxicity.
- Resistance caused by downstream pathway alterations.
- Difficulty demonstrating benefit in combination trials.
No non-BCC indication has become a comparable commercial opportunity for Odomzo.
What is the FDA regulatory status of Odomzo?
Odomzo remains an FDA-approved prescription drug for adults with laBCC that has recurred following surgery or radiation therapy, or for patients who are not candidates for surgery or radiation therapy.
FDA label restrictions
The label includes boxed-warning-level reproductive risks and warnings concerning:
- Embryo-fetal toxicity.
- Premature fusion of epiphyses in pediatric patients.
- Muscle-related adverse reactions.
- Creatine kinase elevation.
- Rhabdomyolysis risk.
- Drug interactions involving CYP3A inhibitors and inducers.
Sonidegib is not approved for pediatric patients. Women of reproductive potential require pregnancy testing and contraception management under the product’s risk controls.[1]
What is the Orange Book status of sonidegib?
Sonidegib is a small-molecule product listed in FDA drug-product and Orange Book systems under Odomzo. Unlike biologic products, follow-on competition would proceed through an abbreviated new drug application rather than a biosimilar application.
The commercial patent assessment should distinguish among:
- Active pharmaceutical ingredient or composition patents.
- Solid-state, salt, or crystal-form patents.
- Capsule formulation patents.
- Methods of treating BCC.
- Manufacturing and process patents.
- Pediatric-exclusivity or regulatory exclusivity periods.
The original approval date does not establish the end of patent protection. The relevant generic-entry date depends on the latest enforceable patent, any patent-term extension, regulatory exclusivity, and the outcome of Paragraph IV litigation.
Paragraph IV risk
A generic applicant could challenge listed patents by filing a Paragraph IV certification alleging that the patent is invalid, unenforceable, or not infringed. A Paragraph IV notice could trigger a 30-month stay of FDA approval if the patent holder files suit within the statutory period.[3]
The risk profile is likely to be higher for formulation and method-of-use patents than for the underlying compound patent as the product matures. Generic applicants commonly seek non-infringing labels that omit patented uses, but label carve-outs are constrained when the protected use is central to the reference product’s approved indication.
When does sonidegib lose exclusivity?
There is no single reliable exclusivity date based only on the FDA approval date. Sonidegib’s market exclusivity is determined by the combined patent and regulatory record.
Exclusivity timeline
| Event |
Date or status |
| U.S. FDA approval |
July 24, 2015 |
| New chemical entity exclusivity |
Five years from approval, subject to applicable patent-certification rules |
| Orphan-drug exclusivity |
Not the basis of the primary BCC approval |
| Patent-term extension |
Must be assessed from the issued patent and PTO record |
| Generic approval timing |
Depends on ANDA filing, listed patents, Paragraph IV litigation, and 30-month stay |
| Biosimilar exclusivity |
Not applicable |
| Commercial loss-of-exclusivity risk |
More dependent on listed patents than on regulatory exclusivity |
The five-year new chemical entity period would have expired in 2020, absent a qualifying extension. Current generic-entry exposure therefore depends primarily on the patent estate and any later-issued patents.
How strong is the patent estate for sonidegib?
The commercial strength of the sonidegib estate is moderate rather than absolute.
Factors supporting patent strength
- Sonidegib is a differentiated chemical entity with an approved oncology use.
- The product may have protection covering formulation, crystalline form, or manufacturing processes.
- The approved indication involves a defined patient population and may support method-of-use claims.
- Patent-term adjustment or extension may have pushed some rights beyond the nominal 20-year term from filing.
Factors weakening patent strength
- The product was approved in 2015, placing it in a mature post-launch period.
- Small-molecule patents can be challenged through ANDA litigation.
- Generic applicants may design around process or formulation claims.
- The label is narrow, making use-based patent enforcement more concentrated.
- Sonidegib competes with an established class alternative, reducing the commercial value of a prolonged litigation campaign.
A complete freedom-to-operate assessment requires a live review of the FDA Orange Book, USPTO Patent Center, patent-family records, terminal disclaimers, patent-term calculations, and any district-court litigation. Patent expiration should not be inferred from the approval date alone.
What patents protect Odomzo?
The relevant protection is expected to include several patent categories rather than a single right:
| Patent category |
Commercial relevance |
| Compound patent |
Protects the sonidegib chemical entity and may provide the earliest core barrier |
| Salt or solid-state patent |
May protect sonidegib phosphate or a specific solid form |
| Pharmaceutical composition patent |
Covers dosage forms, excipients, or capsule compositions |
| Method-of-use patent |
Covers treatment of BCC or Hedgehog-pathway disorders |
| Manufacturing patent |
Can complicate active-ingredient production but may be avoidable |
| Formulation patent |
Can delay or narrow generic substitution if claims are enforceable |
Sonidegib phosphate is particularly relevant to salt and solid-state patent analysis. A generic applicant may seek approval using the same active moiety while challenging or avoiding selected salt, formulation, or process claims.
What formulation patents protect sonidegib?
Odomzo is an oral capsule. Formulation-related protection may address the physical form of sonidegib, drug loading, excipient selection, dissolution characteristics, stability, or capsule composition.
Formulation patents generally have less strategic value than a valid compound patent, but they can affect:
- ANDA design.
- Bioequivalence strategy.
- Manufacturing cost.
- Generic launch timing.
- Substitution at the pharmacy level.
- Litigation settlement leverage.
The practical barrier is strongest when the formulation claim is difficult to design around and the approved label requires that formulation for product performance.
Which companies are challenging sonidegib?
Sonidegib has not generated the level of public Paragraph IV litigation associated with high-volume products such as lenalidomide, ibrutinib, or major GLP-1 therapies. Publicly visible generic challenges should be tracked through FDA Paragraph IV notices, Orange Book patent certifications, PACER, and district-court docket searches.
The likely challengers are generic manufacturers with oncology portfolios, including large ANDA filers and specialty-generic companies. A challenger’s commercial incentive depends on:
- Remaining patent term.
- Expected annual U.S. sales.
- Cost of bioequivalence and manufacturing development.
- Availability of a carve-out label.
- Size of the advanced BCC patient population.
- Probability of obtaining a first-filer advantage.
How does sonidegib compare with vismodegib?
Sonidegib and vismodegib are both oral SMO inhibitors approved for advanced BCC. Vismodegib has earlier market entry and broader historical clinical familiarity. Sonidegib was positioned partly on differentiated exposure and tolerability at the 200-mg dose, but both products have class-related adverse effects.
| Factor |
Sonidegib |
Vismodegib |
| Brand |
Odomzo |
Erivedge |
| Developer |
Novartis |
Genentech/Roche |
| Target |
SMO |
SMO |
| Main approved use |
Advanced BCC unsuitable for surgery/radiation |
Advanced BCC unsuitable for surgery/radiation |
| Administration |
200 mg once daily |
150 mg once daily |
| Key toxicity burden |
Muscle spasms, CK elevation, dysgeusia, alopecia |
Muscle spasms, alopecia, dysgeusia, weight loss |
| Market position |
Secondary Hedgehog inhibitor |
Earlier and more established class product |
| Generic risk |
Small-molecule ANDA exposure |
Small-molecule ANDA exposure |
| Strategic limitation |
Narrow market and treatment discontinuation |
Same class limitations, with longer commercial history |
Neither drug has displaced surgery, radiation, or immune checkpoint therapy in all eligible patients. The choice depends on prior treatment, tumor location, toxicity tolerance, prescriber familiarity, and access.
What is the market size for sonidegib?
Sonidegib addresses a narrow segment of the BCC market. Most BCC cases are treated surgically or with local therapies. Only a small fraction develop disease requiring systemic Hedgehog inhibition.
The addressable population includes patients with:
- Locally advanced tumors unsuitable for surgery.
- Locally advanced tumors for which radiation is inappropriate.
- Recurrent disease after surgery or radiation.
- Metastatic BCC, which is rare.
- Patients unable to receive or tolerate alternative systemic therapy.
The total BCC incidence is large, but the Odomzo-treated population is small. This distinction is critical for valuation. Epidemiological growth in BCC does not translate directly into equivalent sonidegib revenue growth.
What is the sonidegib market forecast?
Public company reporting does not consistently disclose Odomzo revenue as a standalone line item. A defensible forecast therefore requires a bottom-up model rather than a headline market-size estimate.
Base-case commercial outlook
| Driver |
Directional effect |
| Aging population and rising BCC incidence |
Positive |
| Narrow approved population |
Negative |
| Competing vismodegib |
Negative |
| PD-1 therapy in advanced BCC |
Negative to neutral |
| Treatment discontinuation from toxicity |
Negative |
| Price pressure from generic entry |
Strongly negative |
| Specialist awareness |
Positive but limited |
| New approved indications |
Not established |
A reasonable base case is a flat-to-declining branded revenue profile before generic entry, followed by a sharp erosion scenario after the first credible generic launch. The market is unlikely to support sustained high growth without a new indication, a major tolerability improvement, or a combination regimen that changes treatment sequencing.
Generic launch scenarios
| Scenario |
Expected commercial effect |
| No near-term generic approval |
Gradual branded erosion from class competition |
| One generic entrant |
Material price and volume pressure |
| Multiple generic entrants |
Rapid price erosion and substitution |
| Successful patent settlement |
Delayed entry with defined launch date |
| Method-of-use carve-out |
Partial competition, depending on prescribing and substitution rules |
The most important valuation variable is not overall BCC incidence. It is the timing and enforceability of the last commercially relevant patent.
What licensing deals affect sonidegib?
Novartis developed and commercialized sonidegib. The compound originated from the Hedgehog-pathway drug-development work associated with Novartis and related research collaborations. No major current licensing transaction has materially changed the product’s commercial ownership or market structure.
Any future licensing value would likely be tied to:
- Regional commercialization rights.
- Combination development.
- Dermatology or oncology specialty distribution.
- Generic or authorized-generic arrangements.
- A successor formulation with improved tolerability.
The absence of a major new indication limits the strategic value of a broad global licensing deal.
What patent litigation and settlements affect Odomzo?
The commercially relevant litigation question is whether an ANDA filer has challenged an unexpired Orange Book-listed patent and whether the holder has filed suit within the statutory period. Public litigation should be assessed by product name, active ingredient, patent number, ANDA number, and court docket.
For valuation purposes, a settlement can have three outcomes:
- Delayed generic entry with a fixed launch date.
- At-risk launch before patent expiration.
- A license allowing entry under agreed commercial terms.
The third outcome can include royalties, supply arrangements, authorized-generic restrictions, or limits on the generic label. A settlement that preserves several years of exclusivity can be more valuable than a full trial victory if litigation costs and invalidity risk are high.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are meaningful but unlikely to provide permanent protection. Sonidegib production may require control of stereochemistry, impurity profile, solid-state form, particle characteristics, and capsule stability.
A generic manufacturer must establish:
- Pharmaceutical equivalence.
- Bioequivalence.
- Consistent active-ingredient quality.
- Stability through the proposed shelf life.
- Compliance with current good manufacturing practice.
- A legally acceptable patent position.
Process patents can raise development costs but are usually less durable than compound or formulation patents. A generic manufacturer with established oncology manufacturing capacity can often overcome these barriers if the expected market supports development expense.
What generic entry risks exist for sonidegib?
Generic entry risk is high over the medium term because sonidegib is an oral small molecule with a defined dose and no biosimilar complexity. The principal barriers are patent validity, formulation design, bioequivalence, and market size.
The risk is amplified by the limited clinical differentiation between Hedgehog inhibitors. Once an interchangeable or substitutable generic is available, payer and pharmacy pressure can rapidly reduce branded demand.
Key Takeaways
- Sonidegib phosphate is marketed as Odomzo and is approved for adults with laBCC unsuitable for surgery or radiation.
- The BOLT phase II trial established efficacy, with an approximately 43% response rate in the 200-mg laBCC arm at the primary analysis.
- Muscle spasms, creatine kinase elevation, dysgeusia, alopecia, and treatment discontinuation limit use.
- Non-BCC clinical development has not produced a major approved expansion.
- Sonidegib is a small molecule, so generic competition would use the ANDA pathway rather than biosimilar approval.
- The five-year new chemical entity period has expired; current exclusivity depends mainly on active patents and litigation.
- Market growth is constrained by the small systemic BCC population, vismodegib, immune checkpoint therapy, and toxicity.
- The likely commercial trajectory is flat to declining before generic entry and sharply lower after successful generic launch.
- Patent value depends on the surviving compound, salt, formulation, method-of-use, and process claims rather than the FDA approval date alone.
FAQs
Is sonidegib phosphate a chemotherapy drug?
No. Sonidegib is a targeted Hedgehog-pathway inhibitor. It is an oral small-molecule anticancer drug, not a conventional cytotoxic chemotherapy.
Can sonidegib treat metastatic basal cell carcinoma?
It has demonstrated activity in metastatic BCC, but the metastatic population is small and the main commercial use is locally advanced disease. Treatment selection depends on prior therapy, patient condition, and available alternatives.
Is sonidegib better than vismodegib?
Neither drug has established universal superiority. Both inhibit SMO and have overlapping efficacy and class toxicities. Prescribing depends on tolerability, prior exposure, treatment history, access, and clinician preference.
Does sonidegib have a biosimilar?
No. Sonidegib is a small molecule. Follow-on products would be developed as generic drugs through the ANDA process.
Why is sonidegib discontinued so often?
Hedgehog-pathway inhibition commonly causes muscle spasms, taste disturbance, hair loss, weight loss, fatigue, and laboratory creatine kinase elevations. These adverse effects can lead to dose interruptions or treatment discontinuation.
References
-
U.S. Food and Drug Administration. (2015). Odomzo (sonidegib) prescribing information. FDA.
-
Dummer, R., Guminski, A., Gutzmer, R., et al. (2016). The 12-month analysis from the randomized phase II study evaluating sonidegib in patients with advanced basal cell carcinoma. Journal of the American Academy of Dermatology, 75(1), 113-125.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. National Library of Medicine. (2024). ClinicalTrials.gov: Sonidegib clinical studies. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (2024). Hedgehog pathway inhibitors and drug safety communications. FDA.
